Replies to post #7375 on ANI Pharmaceuticals (ANIP)

[smile86]

ITS about time=LUCK to ALL

[jeffqdhsr]

Jadite , these guys are full of surprises !

Their Mantra is " Growth " the message to anyone interested in acquiring ANI is " We are self sustaining " I really enjoy watching how this small Co has grown in a relatively short period , in a highly competitive sector ! It's very impressive

I prefer to see our assets realized before considering a sale , get the job done before considering selling ! I Will wait

JMHO , Happy New Years !!!

[jeffqdhsr]

Jadite take notice to what these drugs address !

About ATACAND HCT® tablets

ATACAND HCT combines an angiotensin II receptor (type AT1) antagonist and a diuretic, hydrochlorothiazide. ATACAND HCT is indicated for:

Treatment of hypertension, to lower blood pressure.
About ARIMIDEX® tablets

ARIMIDEX is an aromatase inhibitor indicated for:

Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
First-line treatment of postmenopausal women with hormone-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.
ARIMIDEX is approved for the initial [ARI uses first] treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.
About CASODEX® tablets

CASODEX is an androgen receptor inhibitor indicated for:

Use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.
CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.
CASODEX 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2)].

[Just the facts maam]

Net income of $8.67 million for Q4. Based on the statement that "As of today, ANI’s cash on-hand and capacity under the revolver provides us with approximately $80 million in available cash.”

$125 million (Credit Facility) - $25 million (what was used from the $30 million credit facility) - $46.5 Million (Astrazeneca products)= 53.3 million

They say they have $80 million cash and credit available that means $26.7 million (cash on hand)

$26.7 Million - $18.03 million (cash on hand from Q3 filing) = $8.67 Million net income.

News

That should catch attention.